Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

Celltex Therapeutics Receives Another FDA Approval: Phase II Clinical Trial Using MSCs a Prophylactic Against COVID-19

June 26, 2020 By Cade Hildreth, Founder & President Leave a Comment

June 26, 2020, HOUSTON — Celltex, a Houston, Texas-based biotechnology company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Company’s Investigational New Drug application (IND 22055) to investigate the Prophylactic Efficacy of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) Against Coronavirus Disease 2019 (COVID-19). [Read more…]

MSCs, The Most Suitable Cells for COVID-19?

May 8, 2020 By Cade Hildreth, Founder & President 1 Comment

Since the outbreak of the new type of coronavirus pneumonia (COVID-19) in December 2019, the scientific community has been working fervently to develop treatments to combat the disease. Globally, scientists are exploring every potential weapon to suppress the global threat. Approaches under investigation include vaccines, medications, combination therapies, and perhaps most interestingly, living therapies with promising cell types such as natural killer (NK) cells, stem cells and exosomes. [Read more…]

Citius to License Novellus’ iPSC-derived MSCs for COVID-19 Related Complications

April 4, 2020 By Cade Hildreth, Founder & President Leave a Comment

– Novellus’ patented mRNA-based cell-reprogramming technology creates MSCs with superior immunomodulatory properties

– Novellus’ iPSC-derived MSCs have manufacturing advantages over primary adult, donor-derived MSCs, allowing for larger supply, faster scale-up, and a more consistent cellular product

– MSCs may remedy the cytokine storm that triggers acute respiratory distress syndrome (ARDS) in COVID-19 patients

[Read more…]

First Patient Dosed in Phase I Clinical Trial using RoosterBio’s Cellular Starting Materials

March 4, 2020 By Cade Hildreth, Founder & President Leave a Comment

Investigational New Drug (IND) Using RoosterBio’s CliniControl™ Products Enters the Clinic by RoosterBio’s Pharmaceutical Customer

RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announces today a significant milestone in the regenerative medicine field with the dosing of the first patient using its innovative cellular starting materials. The patient has been treated by RoosterBio’s pharmaceutical customer with an Investigational New Drug (IND) that was manufactured using RoosterBio’s CliniControl cell and media systems. [Read more…]

Top 10 Quotes from the Perinatal Stem Cell Society Conference

March 4, 2020 By Cade Hildreth, Founder & President 1 Comment

Over the past three days, dozens of world renowned speakers have presented their latest findings at the Perinatal Stem Cell Society Conference, hosted by Kyle Cetrulo of Auxocell Laboratories and the Perinatal Stem Cell Society (IPLASS).

To capture the best moments from the conference, below are the top 10 quotes from the event, which was hosted at Aspen Meadows Resort in Aspen, CO,.

I took the image above as we were landing in Aspen. You can see our full photo album from the event on Flickr, featuring presenters, sponsors, and more. To get live updates from the event, connect with me on Twitter (@StemCellMarket) or follow the hashtag #Perinatal. Enjoy! [Read more…]